SALL4

CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancer Strong preclinical data generated with CT-02 against NEK7 CT-05 potential best-in-class pro high potential / partially de-risked PKCӨ protein pathway Webcast to take place on Thursday 30th March at 4 pm CET / 10 am ET – Registration link below WROCŁAW, Poland, March 28, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today discloses the identity of the drug targets as well as associated supporting data, and provides an update on the progress in the research and development of its pipeline lead programs CT-01, CT-02 and CT-05. Dr Michal Walczak, Chief Scientific Officer and Co-founder of Captor, will present the scientific rational for these targets as well as the market potential of each of Captor’s lead programs and will answer questions during a webcast on March 30th 2023. Webcast invitation to discuss scientific rational and market potential of new targets Date: March 30th 2023 at 4pm CET / 10 am ET Please register by following this link. CT-01 / CPT-6281 targeting GSPT1, SALL4 and (new disclosure) NEK7 CT-01 / CPT-6281 is currently undergoing IND/CTA-enabling studies with the first clinical trial expected to start at the end of 2023. The first indication will be in Hepatocellular Carcinoma (HCC). CPT-6281 is a first-in-class degrader of GSPT1, SALL4, and NEK7. GSPT1 is a protein involved in the termination of translation, SALL4 is a transcription factor often over-expressed in HCC patients and correlating with poor prognosis, and NEK7 is a protein in which degradation leads to a reduction in IL-1b production, a well-known pro-carcinogenic factor. Moreover, CPT-6281 is particularly well suited for liver, lung, and neuroendocrine tumors since it is a prodrug1 activated by an enzyme present in high concentration in the liver, the lungs, and some gastrointestinal tumors. CT-02 targeting (new disclosure) NEK7 In addition to the potential benefits of NEK7 degradation combined with the degradation of GSPT1 and SALL4 in cancer, as mentioned above for the CT- 01 Project, the selective degradation of NEK7 alone in the CT-02 Project has many potential benefits as a treatment of several autoimmune diseases. Such NEK7 degradation allows the modulation of the inflammasome, a complex that plays a critical role in the regulation of the inflammatory response. Captor believes that selective NEK7 degraders have the potential to overcome the limitations shown in the past of NLRP3 inhibitor drugs related to increased susceptibility to infection. Importantly, it is established that NEK7 pro-inflammatory activity is largely driven by its scaffolding function, and because of that, classical inhibition of NEK7’s kinase function doesn’t provide therapeutic benefit. It is therefore expected that selective degradation of NEK7 would also remove the NEK7 scaffolding function leading to potent inflammatory inhibition. Pre-clinical studies have revealed the following benefits of CT-02: Effective NEK7 degradation at low concentrations in vitro (high potency) and ex vivo Degradation of NEK7 is correlated with the desired in-vitro biological effects on the inflammatory response Optimised compounds with good pharmacokinetics in animals have been developed Compounds with the ability to cross the blood-brain-barrier have been identified and provide opportunity for further development in the area of neurodegeneration CT-05 targeting (new disclosure) PKCӨ (PKC theta) CT-05 targets the PKCӨ protein, a protein highly relevant in both autoimmune diseases and cancer. Indeed, PKCӨ plays an important role in the modulation of T cells by limiting the suppressive function of T cells. It is therefore expected that degrading the PKCӨ protein would lead to an increased T cell suppressive function. PKCӨ is a high-value target with opportunities in certain autoimmune diseases, such as allergy, psoriasis, and inflammatory bowel disease, as well as certain malignancies, such as breast and gastrointestinal cancer. Importantly, the approach behind CT-05 is partially de-risked thanks to: the PKCӨ protein acts via the CD3/CD28 – IL-2/IL-17 pathway. The IL-17 pathway is a clinically validated pathway in autoimmune diseases such as psoriasis with established modulators2 the potential of the PKCӨ protein pathway is underpinned by BMS’s latest in-licensing of Exscientia’s PKCӨ inhibitor EXC4318 In preclinical studies, CT-05 has demonstrated attractive features that differentiate CT-05 from inhibitors that failed in clinical trials due to side effects: Potent degradation and first-in-class selectivity pro the molecular target PKCӨ in immune cells in vitro Desired effect on ex vivo immune cells No effect on non-immune cells AboutCaptorTherapeutics Captor Therapeutics is a drug discovery and development company applying targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases with significant unmet medical need. TPD is a revolutionary approach to developing new drugs that can target new molecular targets considered undruggable" using classical drug modalities and provide additional treatment options for diseases where existing drugs do not provide optimal treatment. Captor is currently developing treatments for undertreated serious conditions, including cancer and autoimmune diseases. For more information on Captor Therapeutics, visit: LinkedIn: @CaptorTherapeutics Twitter: @CaptorTherapeu1 Mediaandinvestor contacts: PolishMediaandInvestorRelations: Point of View Bartosz Sawulski +48 694 400 787 captortherapeutics@pov.pl International InvestorRelations: LifeSci Advisors Guillaume van Renterghem +41 (0)76 735 01 31 gvanrenterghem@lifesciadvisors.com 1 A prodrug is a biologically inactive compound which can be metabolized in the body to produce a drug which is pharmacological active. 2 Ixekizumab, Secukinumab, Brodalumab

The big Connect in Pharma conference is coming up and speakers plan to discuss digitization and strategies to bring the European supply chain home and CanSino Biologics, HUTCHMED and more have positive research news. Connect in Pharma The European pharmaceutical industry is coming together to focus on new methods that will remedy supply chain concerns and potentially improve innovations across the sector. Leaders will discuss key issues facing the industry and the means to overcome them. European pharma leaders will gather in Geneva, Switzerland in September at the Connect in Pharma conference to discuss some of these concerns and brainstorm strategies to address them. Keynote speakers will focus on the need to maintain control of production lines and the prioritization of digitalization in order to ensure a strong future for the European industry. Ahead of the conference, Jean-François Hilaire, executive vice president and president of advanced delivery systems at Recipharm, noted that decisions to shift production of key active pharmaceutical ingredients to factories in China and India have left the European pharmaceutical industry exposed to supply chain risks that the COVID-19 pandemic has highlighted. As a result, Hilaire pointed to a need to bring that production back to Europe in order to ensure a "more strategic resilience." Hilaire said this involves hurdles, including capital investment and regulatory approvals that could take years to overcome. "We must retain the development and production of new, innovative products in Europe," Hilaire said. Digitalization is a key part of any future roadmap in Europe, the speakers said. Christian Wölbeling, executive industry advisor and senior strategic account manager at Körber Pharma Software, discussed the strategic case for digital transformation and provided insights on how companies can create digital workflows and increase connectivity so systems can easily talk to each other. He said companies have multiple departments that are not always well-integrated. "All these parts have data, and each system has its own silo. Without a common data platform, end-to-end tracking and tracing is inefficient and difficult," Wölbeling explained ahead of the conference. Connect in Pharma will take place on September 14 and 15 in Geneva. Elsewhere around the globe: CanSino Biologics: Based in China, CanSino announced that it published a paper on the antibody persistence and safety of its nebulized inhaled Recombinant COVID-19 Vaccine on the preprint platform for biomedical research medRixv. Data from the report showed that a heterologous booster of CanSino's nebulized inhaled COVID-19 vaccine could elicit higher antibody levels against the original SARS-CoV-2 strain and the Omicron BA.1.1.529 variant in adults. Previous studies showed that CanSino's nebulized, inhaled COVID-19 vaccine requires only one-fifth or two-fifths of the dosage of the intramuscular injection version. HUTCHMED: Also based in China, HUTCHMED announced a pivotal Phase III trial assessing fruquintinib as a potential treatment for patients with advanced, refractory metastatic colorectal cancer met its primary endpoint of overall survival. In addition to OS, a statistically-significant improvement in progression-free survival, a key secondary endpoint, was observed. The safety pro fruquintinib in FRESCO-2 was consistent with previously reported studies. Full results will be submitted for presentation at an upcoming medical meeting. HUTCHMED and its partner Immagene Biopharmaceuticals also announced that the first U.S. patient was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase inhibitor. The study will assess safety, tolerability, pharmacokinetics and pharmacodynamics. LianBio: Based in Shanghai, with operations in New Jersey, LianBio completed enrollment in the Phase III EXPLORER-CN clinical study of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy. The study's primary endpoint is the change in the Valsalva left ventricular outflow tract (LVOT) gradient from baseline to week 30. Eligible patients are expected to continue in a long-term extension program. Bionomics Limited: Based in Australia, Bionomics Limited received a research and development tax incentive valued at more than $2 million (Australian dollars). The Australian Government R&D tax incentive encourages companies to engage in R&D, benefiting Australia by providing a tax offset of up to 43.5% for eligible R&D activities. CYTENA: BICO company CYTENA, which is based in Germany, launched a new instrument to streamline single-cell isolation in microbiology research. The next generation B.SIGHT is taking the company's automated single-cell isolation capabilities to the next level with special emphasis on handling bacteria, yeast and other microorganisms. CYTENA believes the new B.SIGHT will accelerate and automate microbial cloning workflows across the industry. It will also revolutionize the microbiome field by enabling scientists to streamline their microbiome work and accelerate their path toward transformative medicine. SciSparc: Based in Israel, SciSparc Ltd. received approval from the Israeli Ministry of Health to conduct its clinical trial of SCI-210 in patients with autism spectrum disorder (ASD). The trial will investigate the effect of the company's drug candidate SCI-210, a proprietary combination of cannabidiol and CannAmide, compared to CBD monotherapy in ASD. The 20-week trial has three endpoints, the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire; the Clinical Global Impressions-Improvement (CGI-I) performed by a clinician; and the effective therapeutic dose. Captor Therapeutics: Poland's Captor selected CPT-6281 as a drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma. CPT-6281 is on track to enter the clinical in 2023, the company said. The CT-01 series of molecular glues are compounds inducing degradation of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), Sal-like protein 4 (SALL4) and another undisclosed neo-substrate with an essential function in tumorigenesis. Artios Pharma: Artios Pharma Limited, a U.K.-based company developing small molecules that target the DNA damage response process, initiated a Phase II study with ART4215, a small molecule inhibitor of polymerase theta (Polθ) in combination with Talzenna (talazoparib) in an expansion study for the treatment of BRCA deficient breast cancer. Polθ, a DNA polymerase, is a tumor-specific DDR target involved in microhomology-mediated end joining that is overexpressed in many tumors and found in low levels in healthy tissue, the company said. ART4215 is the first selective, oral, small molecule inhibitor of the Polθ polymerase domain to enter the clinic.

WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment of cancer and autoimmune diseases, today announces that it has selected CPT-6281 as drug candidate for the CT-01 project, which will initially focus on the clinical development of the asset as a TPD treatment against hepatocellular carcinoma (HCC). The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023. As disclosed earlier this year, the CT-01 series of molecular glues are compounds inducing degradation of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), Sal-like protein 4 (SALL4) and another undisclosed neo-substrate with essential function in tumorigenesis. Earlier this year, Captor reported very promising in vitro and in vivo preclinical data demonstrating the high anti-tumor activity at low doses of the two lead compounds in a mouse model of human liver cancer, when administered orally. Captor went through additional extensive in vitro and in vivo evaluations to help selecting CPT-6281 as the candidate most likely to provide significant therapeutic benefit, combined with minimal or no off-target degradation and a suitable back-up compound was also identified. Following the selection of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization. The CDMO will produce sufficient amounts of drug candidate to complete the preclinical studies required to support a clinical trial application filing with the regulators next year. “The nomination of our first drug candidate is another and very satisfying milestone in the Company's history, demonstrating the results of several years of systematic work on targeted protein degradation. In the CT-01 project, we are entering the advanced stage of preclinical development of the drug candidate, i.e. work whose results will be included in the IND studies, and will open the way for us to start the first phase of clinical trials,” commented Dr. Michał Walczak, Co-Founder and Chief Scientific Officer of Captor Therapeutics. “Captor is progressing according to plan and will deliver on its promises to enter the clinical phase in 2023. The team has done a tremendous job in delivering a highly potent, highly selective and highly differentiated lead drug candidate, targeting crucial proteins involved in solid cancers with high unmet medical need. I believe the clinical data that will be generated in the coming years could bring new hope to the many patients affected with hepatocellular carcinoma,” said Dr. Tom Shepherd, Chief Executive Officer of Captor Therapeutics. “Beyond the progress made with our molecular glue CT-01, Captor’s team is also working tirelessly to develop other drug candidates, be they glue, bi-functional degraders, or new ligases. These candidates aim to tackle solid and liquid tumors as well as autoimmune diseases and are positioning Captor as a true innovator in the Targeted Protein Degradation space,” added Dr. Shepherd. About Captor Therapeutics Captor Therapeutics is a biopharmaceutical company dedicated to using targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases deemed as medically uncurable. TPD is a revolutionary approach to developing new drugs that can target new molecular targets considered "untreatable" using classical drug development methods and provide additional treatment options for diseases where existing drugs do not provide optimal medical benefit. Captor is currently developing treatments for undertreated serious conditions, including malignancies and autoimmune diseases. For more information on Captor Therapeutics, visit: http://www.captortherapeutics.com